A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 8 → 12 locations
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 3 of 13 entries
  2. Study sites: 7 to 8v11
  3. Eligibility criteria shortened, about 3 wordsv10
  4. Study sites: 6 to 7v9
  5. Study sites: 5 to 6v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 4 to 5v7
  2. Eligibility criteria expanded, about 23 wordsv6
  3. Re-verified, no change to tracked fieldsv5
  4. Start date changed from estimate of Jul 2025 to Aug 18, 2025v4
  5. Study sites: 3 to 4v3
  6. Study sites: 2 to 3v2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ALX Oncology Inc.
5 trials monitored
See all monitored trials
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,085 trials monitored
See 178 trials at risk
and 2 more diseases
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Trial Details
NCT Number NCT07085091
Lead Sponsor ALX Oncology Inc.
Conditions
(from sponsor)		 NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Related terms Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Colorectal Neoplasms, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Neoplasm Metastasis, Squamous Cell Carcinoma of Head and Neck
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov